Israel's Upcoming Eur300 Million Bond Rated 'A-'; Ratings Affirmed; Outlook Stable Jun 99

  • ID: 2045353
  • June 1999
  • Region: Israel
  • Standard & Poors
1 of 3

LONDON (Standard & Poor's CreditWire) June 7, 1999--Standard & Poor's today assigned its single-'A'-minus rating to the State of Israel's upcoming euro (Eur) 300 million bond issue. At the same time, Standard & Poor's affirmed its double-'A'-minus local currency and its single-'A'-minus foreign currency long-term issuer credit and senior unsecured ratings on Israel. Standard & Poor's also affirmed its 'A-1'-plus local currency and its 'A-1' foreign currency short-term issuer credit ratings on Israel. The outlook is stable. Israel's ratings are supported by: -- A diversified and well-developed economy, which is increasingly broad-based and technology-oriented. -- Substantial progress in structural reforms, particularly bank privatization and capital account liberalization. With the fading growth contribution of immigration from the former Soviet Union, setbacks...

Companies mentioned in this report are:
- Israel (State of)

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Israel (State of)

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.